Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 3, 2008, Pages 285-292

  Yi, Yanjie ^a   Loftin, Lamorris ^a   Wang, Lingshu ^a   Ratcliffe, Sarah J ^a   Isaacman Beck, Jesse ^a   Collman, Ronald G ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 522 Johnson Pavilion ^*  (United States)

Author keywords

Chemokine receptor; Enfuvirtide; gp120; Macrophage; R5X4; Viral entry

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; ENVELOPE PROTEIN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; VIRUS STRAIN; DOSE RESPONSE; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; LONG TERMINAL REPEAT; METABOLISM; METHODOLOGY; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VIROLOGY;

ANTIGENS, CD4; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; MACROPHAGES; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; RECEPTORS, CCR5; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION;

EID: 42449119376     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31816520f6     Document Type: Article

References (30)

1. Stalmeijer EH, Van Rij RP, Boeser-Nunnink B, et al. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J Virol. 2004;78:2722-2728.
2. Matthews T, Salgo M, Greenberg M, et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov. 2004;3:215-225.
3. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA. 2002;99:16249-16254.
4. Beausejour Y, Tremblay MJ. Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane. J Infect Dis. 2004;190:894-902.
5. Heredia A, Gilliam B, DeVico A, et al. CCR5 density levels on primary CD4 T cells impact the replication and enfuvirtide susceptibility of R5 HIV-1. AIDS. 2007;21:1317-1322.
6. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol. 2000;74:8358-8367.
7. Xu Y, Zhang X, Matsuoka M, et al. The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41. FEBS Lett. 2000;487:185-188.
8. Cilliers T, Patience T, Pillay C, et al. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses. 2004;20:477-482.
9. Yi Y, Shaheen F, Collman RG. Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes. J Virol. 2005;79:1480-1486.
10. Yi Y, Rana S, Turner JD, et al. CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1. J Virol. 1998;72:772-779.
11. Collman R, Hassan NF, Walker R, et al. Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. J Exp Med. 1989;170:1149-1163.
12. Bjorndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol. 1997;71:7478-7487.
13. Gao F, Morrison SG, Robertson DL, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol. 1996;70:1651-1667.
14. Yi Y, Chen W, Frank I, et al. An unusual syncytia-inducing human immunodeficiency virus type 1 primary isolate from the central nervous system that is restricted to CXCR4, replicates efficiently in macrophages, and induces neuronal apoptosis. J Neurovirol. 2003;9:432-441.
15. Finke PE, Caldwell C, Dorn C, et al. The discovery of potent human CCR5 antagonists. Presented at: 10th National Conference of the Inflammation Research Association; 2000; Hot Springs, VA.
16. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med. 1999;5:204-210.
17. Veazey RS, Klasse PJ, Ketas TJ, et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med. 2003;198:1551-1562.
18. Heil ML, Decker JM, Sfakianos JN, et al. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol. 2004;78:7582-7589.
19. Lee B, Sharron M, Montaner LJ, et al. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA. 1999;96:5215-5220.
20. Gallo SA, Puri A, Blumenthal R. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry (Mosc). 2001;40:12231-12236.
21. Doranz BJ, Baik SSW, Doms RW. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol. 1999;73:10346-10358.
22. Baik SSW, Doms RW, Doranz BJ. HIV and SIV gp120 binding does not predict coreceptor function. Virology. 1999;259:267-273.
23. Simmons G, Reeves JD, Hibbitts S, et al. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev. 2000;177:112-126.
24. Melikyan GB, Platt EJ, Kabat D. The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment. Retrovirology. 2007;4:55.
25. Ghezzi S, Menzo S, Brambilla A, et al. Inhibition of R5X4 dual-tropic HIV-1 primary isolates by single chemokine co-receptor ligands. Virology. 2001;280:253-261.
26. Zhang Y, Lou B, Lal RB, et al. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol. 2000;74:6893-6910.
27. Glushakova S, Yi Y, Grivel JC, et al. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. J Clin Invest. 1999;104:R7-R11.
28. Igarashi T, Donau OK, Imamichi H, et al. Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. J Virol. 2003;77:13042-13052.
29. Lapham CK, Zaitseva MB, Lee S, et al. Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5. Nat Med. 1999;5:303-308.
30. Lee S, Lapham CK, Chen H, et al. Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophage-tropic isolates of human immunodeficiency virus type 1. J Virol. 2000;74:5016-5023.